CompanyGLUENasdaqBoston, MA

Monte Rosa Therapeutics, Inc

Monte Rosa Therapeutics develops molecular glue degrader small molecules targeting autoimmune, inflammatory, and oncology diseases.

SEC EDGAR ClinicalTrials.gov monterosatx.com

8-KOct 1Latest SEC filing

Oct 1Latest story

October 2026

Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk study

Oct 1Clinical readoutMonte Rosa Therapeutics, Inc

September 2026

Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's disease

Sep 8Clinical readoutMonte Rosa Therapeutics, Inc Novartis

August 2026

Monte Rosa reports Q2 2026 results as MGD pipeline advances on three fronts

Aug 6Quarterly updateMonte Rosa Therapeutics, Inc

Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancer

Aug 4Trial updateapalutamide Monte Rosa Therapeutics, Inc